Review of anti-vEGF therapy in proliferative diabetic retinopathy

Maria Stephanie R Jardeleza, Joan W. Miller

Research output: Contribution to journalArticle

69 Citations (Scopus)

Abstract

Proliferative diabetic retinopathy (PDR) is a visually significant complication of diabetes mellitus. Pan-retinal photocoagulation (PRP) remains the standard treatment of choice. However, adverse effects of and clinical barriers to PRP have led to exploration of alternative and adjunctive therapeutic strategies in the treatment of proliferative disease. Inhibition of ocular vascular endothelial growth factor (VEGF) has emerged as a promising treatment modality for PDR. This review summarizes results from published studies using intravitreal anti-VEGF agents singly and in combination with standard therapeutic regimens in the treatment of proliferative diabetic retinopathy.

Original languageEnglish (US)
Pages (from-to)87-92
Number of pages6
JournalSeminars in Ophthalmology
Volume24
Issue number2
DOIs
StatePublished - Mar 2009
Externally publishedYes

Fingerprint

Diabetic Retinopathy
Vascular Endothelial Growth Factor A
Light Coagulation
Therapeutics
Diabetes Complications

Keywords

  • Anti-VEGF treatment
  • Proliferative diabetic retinopathy
  • Vascular endothelial growth factor

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Review of anti-vEGF therapy in proliferative diabetic retinopathy. / Jardeleza, Maria Stephanie R; Miller, Joan W.

In: Seminars in Ophthalmology, Vol. 24, No. 2, 03.2009, p. 87-92.

Research output: Contribution to journalArticle

Jardeleza, Maria Stephanie R ; Miller, Joan W. / Review of anti-vEGF therapy in proliferative diabetic retinopathy. In: Seminars in Ophthalmology. 2009 ; Vol. 24, No. 2. pp. 87-92.
@article{f54461988e8d43ca89aad9e6aab74902,
title = "Review of anti-vEGF therapy in proliferative diabetic retinopathy",
abstract = "Proliferative diabetic retinopathy (PDR) is a visually significant complication of diabetes mellitus. Pan-retinal photocoagulation (PRP) remains the standard treatment of choice. However, adverse effects of and clinical barriers to PRP have led to exploration of alternative and adjunctive therapeutic strategies in the treatment of proliferative disease. Inhibition of ocular vascular endothelial growth factor (VEGF) has emerged as a promising treatment modality for PDR. This review summarizes results from published studies using intravitreal anti-VEGF agents singly and in combination with standard therapeutic regimens in the treatment of proliferative diabetic retinopathy.",
keywords = "Anti-VEGF treatment, Proliferative diabetic retinopathy, Vascular endothelial growth factor",
author = "Jardeleza, {Maria Stephanie R} and Miller, {Joan W.}",
year = "2009",
month = "3",
doi = "10.1080/08820530902800330",
language = "English (US)",
volume = "24",
pages = "87--92",
journal = "Seminars in Ophthalmology",
issn = "0882-0538",
publisher = "Informa Healthcare",
number = "2",

}

TY - JOUR

T1 - Review of anti-vEGF therapy in proliferative diabetic retinopathy

AU - Jardeleza, Maria Stephanie R

AU - Miller, Joan W.

PY - 2009/3

Y1 - 2009/3

N2 - Proliferative diabetic retinopathy (PDR) is a visually significant complication of diabetes mellitus. Pan-retinal photocoagulation (PRP) remains the standard treatment of choice. However, adverse effects of and clinical barriers to PRP have led to exploration of alternative and adjunctive therapeutic strategies in the treatment of proliferative disease. Inhibition of ocular vascular endothelial growth factor (VEGF) has emerged as a promising treatment modality for PDR. This review summarizes results from published studies using intravitreal anti-VEGF agents singly and in combination with standard therapeutic regimens in the treatment of proliferative diabetic retinopathy.

AB - Proliferative diabetic retinopathy (PDR) is a visually significant complication of diabetes mellitus. Pan-retinal photocoagulation (PRP) remains the standard treatment of choice. However, adverse effects of and clinical barriers to PRP have led to exploration of alternative and adjunctive therapeutic strategies in the treatment of proliferative disease. Inhibition of ocular vascular endothelial growth factor (VEGF) has emerged as a promising treatment modality for PDR. This review summarizes results from published studies using intravitreal anti-VEGF agents singly and in combination with standard therapeutic regimens in the treatment of proliferative diabetic retinopathy.

KW - Anti-VEGF treatment

KW - Proliferative diabetic retinopathy

KW - Vascular endothelial growth factor

UR - http://www.scopus.com/inward/record.url?scp=66149139466&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=66149139466&partnerID=8YFLogxK

U2 - 10.1080/08820530902800330

DO - 10.1080/08820530902800330

M3 - Article

C2 - 19373692

AN - SCOPUS:66149139466

VL - 24

SP - 87

EP - 92

JO - Seminars in Ophthalmology

JF - Seminars in Ophthalmology

SN - 0882-0538

IS - 2

ER -